Biologics represent a powerful and innovative class of therapeutics in the fight against chronic disease and their sales are projected to reach $326 billion by 2022 – roughly 30% of global prescription drug sales. Biologics tend to be highly selective, effective, and have fewer side-effects than conventional drugs. However, their chemical structure makes them challenging to administer using oral delivery, so the accepted standard of care is needle-based delivery methods, particularly intravenous injection. Christophe Pierlot of Pall Biotech discusses how subcutaneous delivery will become a routine option for both novel and legacy drugs.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2020/07/How-the-Biopharmaceutical-Industry-is-Responding-to.pdf”]